title: [Glucan solution nasal spray vs saline in the treatment of chronic rhinosinusitis: a multi-centric double blind randomised clinical trial].
abstract: OBJECTIVE
  The aim of our study was to evaluate the efficacy of 30 days treatment with glucan solution nasal spray vs. saline in the treatment of signs and symptoms of chronic rhinosinusitis.
  
  
  METHODS
  100 patients affected by chronic rhinosinusitis were enrolled. At the beginning and at the end of the study were evaluated: nasal congestion, headache, rhinorrea, facial pain, rhinopharyngeal exudate, inferior turbinate hypertrophy; a complete instrumental analysis of nasal functions by Active Anterior Rhinomanometry, nasal Muco-Ciliary Transport time and scraping of nasal mucosa was also performed. The patients were randomized 1:1 for receiving intranasal saline or intranasal glucan solution spray. Treatment was administered as follows: 2 puffs/nostril 3 times a day for 30 days.
  
  
  RESULTS
  The patients in therapy with the glucan solution showed a significant improvement concerning rhinorrea facial pain, intensity of headache, inferior turbinate hypertrophy, rhinopharyngeal exudates, inspiratory/expiratory nasal resistences, Muco-ciliary transport time, normalization of nasal mucosas and rhinocytogram; saline lavage didn't show this effects. Both treatment improved rhinorrea, instead both treatment didn't affect nasal congestion.
  
  
  CONCLUSIONS
  According to the results of our multicentric double blind randomized study, we suggest the use of glucan solution nasal spray as an efficacious therapeutic tool in the management of nasal symptoms in patients affected by chronic rhinosinusitis.
authors.affiliation: Istituto di Otorinolaringoiatria, Università di Siena, Policlinico Le Scotte, Siena, Italia. passali@unisi.it
authors.forename: D
authors.initials: D
authors.lastname: Passali
authors.forename: R
authors.initials: R
authors.lastname: Fiorella
authors.forename: A
authors.initials: A
authors.lastname: Camaioni
authors.forename: G
authors.initials: G
authors.lastname: Villari
authors.forename: E
authors.initials: E
authors.lastname: Mora
authors.forename: G C
authors.initials: GC
authors.lastname: Passali
authors.forename: F M
authors.initials: FM
authors.lastname: Passali
authors.forename: A
authors.initials: A
authors.lastname: Crisanti
authors.forename: L
authors.initials: L
authors.lastname: Bellussi
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D005936:Glucans / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D012220:Rhinitis / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy*; D012965:Sodium Chloride / Q000008:administration & dosage*
chemical_list: D005936:Glucans; D012965:Sodium Chloride